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Background: Familial hypercholesterolemia (FH) is a human monogenic disease induced by a variety of mutations
with striking genetic diversity. Despite this variability recurrent mutations occur in each population studied, which
allows both elucidating prevalent mutations and developing DNA diagnostic tools for the disease. Recent research
of FH in St. Petersburg, Moscow and Novosibirsk (major cities in Russia) demonstrates that each megapolis has its
own FH mutation spectrum sharing only small part of mutations with other populations in Russia and Europe. In
order to optimize molecular-genetic diagnostic protocols for FH in Russia we studied mutation spectrum in other
regions including Petrozavodsk, a smaller town in relatively close proximity to St. Petersburg.
Methods: The principal method was automated detection of single-strand conformation polymorphism followed
by direct PCR amplified DNA sequencing.
Results: Twelve different mutations of the low density lipoprotein (LDL) receptor gene were detected in the
Petrozavodsk sample (80 patients). Out of these twelve mutations, seven have never been described before
(c.192_201delinsGGACTTCA, c. 195_196insT, c. 618 T > G, c. 1340C > G, c. 1686_1693delinsT, c. 1936C > A, c.
2191delG). Other five mutations (c. 58G > A, c. 925_931del, c. 1194C > T, c. 1532 T > C, c. 1920C > T) were previously
characterized elsewhere. All new mutations are considered to be a probable cause of the FH in their carriers. Direct
evidence of the neutral character of c.58G > A or p. (Gly20Arg) is provided for the first time. Each pathogenic
mutation was a trait of its own unique pedigree and so far has not been found in other patients.
Conclusions: Strikingly, out of twelve mutations characterized in the Petrozavodsk sample only one mutation, c.
925_931del, has previously been found in patients from St. Petersburg and Finland (most closely located studied
populations), suggesting some common roots in origin of these populations in the past or limited gene exchange
between them nowadays. No recurrent mutations were detected.Background
Familial hypercholesterolemia is a dominant inborn error
of metabolism due to LDL lowered catabolism via specific
LDL receptor. The disease is quite common (1:500) and
can be diagnosed by detection of mutations in LDL recep-
tor gene [1]. More than a thousand different mutations* Correspondence: michail@MM13666.spb.edu
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reproduction in any medium, provided the orhave been characterized in Europe [2-6], their spectra
demonstrating ethnic specificity as well as importance of
the founder effect. In Russia only patients from three cit-
ies: St. Petersburg [7], Moscow [8] and Novosibirsk [9],
were studied showing high heterogeneity of the disease
within the country. In order to search for ethnic muta-
tions and to improve the DNA diagnostics of FH we car-
ried out the mutation spectra characterization in the city
of Petrozavodsk, Republic of Karelia, Russia.
Methods
We collected DNA samples from 80 hypercholesterol-
emic patients from Petrozavodsk city demonstrating atral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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history of hypercholesterolemia and coronary heart dis-
ease; (2) high serum cholesterol, usually higher than
8 mM; (3) the presence of stigmata as corneal arcus, ten-
don xanthomata or xanthelasma. All patients signed an
informed consent for the study. Research was performed
in compliance with the Helsinki Declaration and ap-
proved both by Petrozavodsk State University and Insti-
tute of Experimental Medicine ethics committees. DNA
was isolated from peripheral blood mononuclear cells
nuclei using standard method with phenol-chloroform
extractions [7,10]. All exons and promoter of the LDL
receptor gene were amplified in separate PCR with the
help of Cy-5 labelled oligonucleotide primers as de-
scribed [7] and subjected to SSCP analysis on ALFEx-
press DNA automated sequencer (Life Sciences). Gels
were interpreted with the help of ALFWin DNA
Fragment Analyzer program. Samples demonstrating
shifted mobilities in SSCP analysis were gel-purified and
sequenced by Sanger method on contract terms at
Eurogen Co. (Moscow).Results
Total of 18 sequence variations were found in the
Petrozavodsk FH sample (Table 1). Lipid data of the pa-
tients with specific LDL receptor mutations are listed in
Additional file 1. APOB R3500Q mutation common for
FH in Europe was not found in FH patients from Karelia
in the studied sample. For majority of variations in nu-
cleotide sequence detected, rapid detection methods by
RFLP analysis were developed (Table 1). Presence of the
specific mutation was confirmed by restriction analysis
using enzymes commercially available from Sibenzyme
(Novosibirsk, Russia). The isoschizomers used and their
prototypes are listed in Additional file 2. Effect of muta-
tions on protein function was predicted using various
programs in silico (Additional file 3) and by segregation
analysis.Discussion
Several novel mutant alleles that have been characterized
in our study contain frameshifts, which results in occur-
rence of premature nonsense-codons (see Table 1). Besides
detecting a well-characterized allele FH-North Karelia [12],
a number of new mutations were identified in our study,
including c.192_201delinsGGACTTCA (c.192del10/ins8),
c.195_196insT, c.1686_1693del/insT (c.1686del8/insT) and
c.2191delG. The deleterious character of these mutations
seems likely since they cause a translation frameshift and
formation of a premature termination codon (Table 1).
Usual mechanism of action of a mutation introducing a
premature codon is the nonsense-mediated decay of the
corresponding transcript.Of special interest, however, are missense-mutations
that hamper the LDL receptor function. Analysis of
these mutations (Additional file 3) by PROVEAN, Poly-
Phen, Mutation t@ster and SiftBlink gave somehow dif-
ferent predictions about pathogenicity of these missense
mutations.
All of the methods agreed that p. (Gly20Arg) is a neu-
tral variant. p. (Gly20Arg) mutation was first described
among other disease-causing mutations by Amsellem
et al. [13] in France and later reported from New
Zealand [14], from the Netherlands [15], from Turkey
[16] and from Austria [17]. Despite that Gly-20 of the
signal sequence is conserved in a number of animals,
such as chimp, monkey, rat, rabbit and hamster, the
most recent publications e.g. [18] consider it as a poly-
morphism. However, no segregation data were available
and no direct functional analysis of the mutated protein
was ever performed. In our sample p. (Gly20Arg)
mutation was found in a genetic compound with very
well characterized disease-causing mutation FH-North
Karelia. Proband’s father carried only FH-North Karelia
mutation and had quite typical atherogenic lipid plasma
profile. In a reference patient p. (Gly20Arg) mutation
was also present, but the profile was typical for hetero-
zygous rather than homozygous FH. The mother of the
genetic compound was not available for DNA analysis,
but according to personal communication, she had no
FH features. Therefore, these data are probably the first
direct evidence that p. (Gly20Arg) mutation inherited by
the proband from a healthy mother is a neutral non-FH
causing variant.
Exact predictions regarding a function of the other mis-
sense mutations were not available using in silico analysis
(Additional file 3). However, we believe that substitutions
p. (Ser447Cys), p. (Leu646Ile), p. (Ser206Arg) and p.
(Leu511Ser) resulted in the development of the FH pheno-
type. It’s important to note that p. (Ser447Cys) mutation
introduces a novel cysteine residue, and it could affect
specific Cys-Cys bonding in the EGF precursor homology
domain of the LDL receptor. Another mutation, p.
(Ser206Arg), introduces a large positively charged side
chain into strongly conserved ligand-binding repeat 5
(LR5) of the receptor. Mutation p. (Leu646Ile) doesn’t
change the charge of the receptor molecule, but it pro-
vides for the substitution of the short aliphatic chain by
the branched analogue that potentially could result in
misfolding of the receptor protein. Allele p. (Leu511Ser)
has previously been classified as a pathogenic variant FH
Rome-4 in an Italian patient [19].
There were several variants in the LDL receptor exons
predicted to be silent mutations due to preservation of
the codon sense. However, a synonymous variant p.
(Asn591=) (c. 1773C > T, also known as rs688) was
shown not only to direct alternative splicing of mRNA
Table 1 List of mutations and polymorphisms in the LDL receptor gene in Petrozavodsk FH sample and methods of
their detection
Mutation, systematic name
[name according to Yamamoto
nomenclature] [11]








p. (Gly20Arg) [=p. G(−2)R] c.58 G > A exon 1 Fau I
France, Austria, The Netherlands,
New Zealand, Turkey, Croatia
1 (1)
p. (Ser206Arg) [=p.S185R] c.618 T > G exon 4B Bse21 I None (New) 1 (1)
p. (Ser447Cys) [=p. S426C] c.1340C > G exon 9 BslFI None (New) 1 (2)
p. (Leu511Ser) [=p. L490S] c.1532 T > C exon 10B AclI Italy 1 (1)
p. (Leu646Ile) [=p. L625I] c.1936C > A exon 13 SSCP None (New) 2 (2)
Frameshift mutations
p. (Ser65Glyfs*64) [=FsS44:D108X] c.192_201delinsGGACTTCA exon 3 Hph I None (New) 1 (2)
p. (Val66Cysfs*64) [=FsV45:D108X] c.195_196insT exon 3 SSCP None (New) 1 (1)
p. (Pro309Lysfs*59) [=FsE287: V348X]
(FH North Karelia)
c.925_931del exon 6 Bcc I
Finland, Sweden, USA, St.
Petersburg
1 (2)
p. (Trp562Cysfs*5) [=FsW541:L547X] c.1686_1693delinsT exon 11 Hae III None (New) 1 (2)
p. (Val731Serfs*6) [=FsV710:V715X] c.2191delG exon 15 SSCP None (New) 1 (2)
Putative splice site mutations or neutral mutations
p. (Asn591=) [=p.N570N] c. 1773C > T exon 12 Hinc II USA, China, Morocco, etc. 16%
Neutral mutations/polymorphisms





p. (Ile398=) [=p. I377I] c.1194C > T exon 9 Bse3D I Austria 4 (4)
p. (Arg471=) [=p. R450R] c.1413 G > A exon 10A BslFI
South Africa, Japan, Russia,
Morocco etc.
34%
p. (Pro539=) [= p. P518P] c.1617C > T exon 11 BspACI Morocco, China, Russia, etc. 5%
p. (Asn640=) [=p. N619N] p.1920C > T exon 13 Sse 9 I Hispania, Austria. 1 (2)




p. (Arg744=) [=p. R723R] c.2232 G > A exon 15 Msp I Germany, China. 21%
Footnote: SSCP – single-strand conformation polymorphism analysis. Numeration of nucleotides and aminoacids follows modern nomenclature (numerals accord-
ing to Yamamoto’s nomenclature [11] are given in brackets.
Footnote: Asterisk indicates that the codon with frameshift is followed by several non-wildtype codons up to newly appeared termination codon. For example,
script p. (Trp562Cysfs*5) indicates that the frameshift occurs in codon 562 for tryptophan that is changed to codon for cysteine and is followed by 5 non-wildtype
codons prior to termination codon.
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to reduce the uptake of fluorescently labeled LDLs by
25%. This polymorphism was associated with increased
plasma total and LDL cholesterol in several populations
and so far can’t be considered a neutral nucleotide sub-
stitution [20]. However, p. (Asn591=) variant was found
at a similar frequency in the St.Petersburg FH cohort
and in the control group and thus unlikely is a disease-
causing variant (M.Y. Mandelshtam, unpublished data).
No data suggesting functional role of other silent mu-
tations have been published. This is also true for p.
(Ala391Thr) (c.1171G > A variant), cited previously as p.A370T mutation or StuI RFLP [21-23]. A minor allele of
this polymorphism was found in a number of popula-
tions including Russian population [22], and it was dem-
onstrated in major studies to have no influence on
plasma lipid levels or cardiovascular risk in UK men
[23]. Variant p.(Pro539=) (c. 1617C > T) was detected
only once in St. Petersburg [7] among 80 FH probands
and therefore, was regarded as a silent mutation. How-
ever, in the Petrozavodsk FH sample that rare allele oc-
curs at a higher frequency (5%) and is further considered
to be a DNA polymorphism. As shown in Table 1, p.
(Pro539=) variation can be easily detected as AciI
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site is lost; the PCR-amplified exon 11 of the LDLR gene
is not cut and looks as a single band of 169 bp.
Other silent variants of the LDL receptor gene were
previously characterized as neutral and were not associ-
ated with the disease; this is true for c.1413G > A or p.
(Arg471=) polymorphism in exon 10A known as BslFI
RFLP [24,25]), c.1959C > T transition or p.(Val653=)
variant cited in many sources as AvaII RFLP or Sau 96 I
RFLP, and c.2232G > A or p.(Arg744=) transition known
as MspI RFLP [26]. All these variants have been reported
both for Caucasian and Chinese populations [27].
Conclusions
Considering epidemiology of FH in the Petrozavodsk
population we can conclude that the FH cohort is very
heterogeneous, showing no predominant FH-causing mu-
tations. It seems that known mutations from Finnish
population are only a rare cause of the disease in the Kare-
lian FH sample; the same is true about the St. Petersburg
FH collection [7]. Because no founder effect was detected
in the Karelian FH sample, the rationale for FH diagnos-
tics dictates direct sequencing of the full coding region of
the gene and exon/intron boundaries rather than testing
for known mutations. Modern DNA sequencing technolo-
gies allow performing such analysis quickly and at a rela-
tively low price.
Additional files
Additional file 1: Lipid data of patients with LDL receptor
mutations from Petrozavodsk sample.
Additional file 2: Enzymes used in RFLP analysis for mutation
validation.
Additional file 3: In silico predictions of effects of the nucleotide
substitutions found in the LDL receptor gene in Petrozavodsk FH
sample.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TYuKo, ASG, MYuM performed cloning, SSCP, sequencing and familial
analysis, VAK and TYuKu selected patients for analysis, VBV and MYuM
participated in the study design and coordination and also have written the
paper. All authors read and approved the final manuscript.
Acknowledgements
This research was supported by the Grant of the Russian Foundation for
Basic Research (grant no.10-04-00563 and 13-04-00902). The research was
performed within the frames of the program “Strategical Development of
Petrozavodsk State University”. Dr. Olga Potapova is thanked for improving
the language of the paper. Special thanks are addressed to reviewers, Dr.
Mathilde Varret and Dr. George Dedoussis for their critical comments that
helped making the manuscript better.
Author details
1Department of Molecular Genetics, Institute for Experimental Medicine, NW
Branch of Russian Academy of Medical Sciences, Pavlov Street, 12, St.
Petersburg 197376, Russia. 2Department of Faculty Therapy, Infectiousdiseases and Epidemiology, Petrozavodsk State University, Lenin Street, 33,
Petrozavodsk, Republic of Karelia 185910, Russia. 3Department of
Biochemistry, St.Petersburg State University, Universitetskaya nab., 7/9, St.
Petersburg 199034, Russia.
Received: 25 March 2013 Accepted: 19 December 2013
Published: 27 December 2013References
1. Goldstein JL, Hobbs HH, Brown MS: Familial hypercholesterolaemia. I. In
The metabolic and Molecular Basis of Inherited Disease. Volume III. Edited by
Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw Hill;
2001:2863–2914.
2. Dedoussis GVZ, Schmidt H, Genschel J: LDL-receptor mutations in Europe.
Hum Mutat 2004, 24:443–459.
3. The Low Density Lipoprotein Receptor (Ldlr) Gene in Familial
Hypercholesterolemia. [http://www.ucl.ac.uk/ldlr/Current/]
4. Wilson DJ, Gahan M, Haddad L, Heath K, Whittall RA, Williams RR,
Humphries SE, Day IN: A World Wide Web site for low-density lipoprotein
receptor gene mutations in familial hypercholesterolemia: sequence-
based, tabular, and direct submission data handling. Am J Cardiol 1998,
81(12):1509–1511.
5. Universal Mutation Database. [http://www.umd.be/LDLR/]
6. Villéger L, Abifadel M, Allard D, Rabès JP, Thiart R, Kotze MJ, Béroud C,
Junien C, Boileau C, Varret M: The UMD-LDLR database: additions to the
software and 490 new entries to the database. Hum Mutat 2002,
20(2):81–87.
7. Zakharova FM, Damgaard D, Mandelshtam MY, Golubkov VI, Nissen PH,
Nilson GG, Stenderup A, Lipovetsky BM, Konstantinov VO, Denisenko AD,
Vasilyev VB, Faergeman O: Familial hypercholesterolemia in St.
Petersburg: the known and novel mutations found in the low density
lipoprotein receptor gene in Russia. BMC Med Genet 2005, 6((1):6.
http://www.biomedcentral.com/1471-2350/6/6.
8. Meshkov AN, Stambol’skii DV, Krapivner SR, Bochkov VN, Kukharchuk VV,
Malyshev PP: [Low density lipoprotein receptor gene mutations in
patients with clinical diagnosis of familial hypercholesterolemia].
Kardiologiia 2004, 44:58–61 [Article in Russian].
9. Voevoda MI, Kulikov IV, Shakhtshneider EV, Maksimov VN, Pilipenko IV,
Tereschenko IP, Kobzev VF, Romaschenko AG, Nikitin YP: The spectrum of
mutations in the low-density lipoprotein receptor gene in the Russian
population. Rus J Genet 2008, 44(10):1191–1194. Translated from: Genetika.
44:1374–1378.
10. Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ, Breg
WR, Jones HW, Rary JM: Analysis of human Y-chromosome-specific reiter-
ated DNA in chromosome variants. Proc Natl Acad Sci USA 1977,
74:1245–1249.
11. Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL,
Russell DW: The human LDL receptor: a cysteine-rich protein with mul-
tiple Alu sequences in its mRNA. Cell 1984, 39:27–38.
12. Koivisto UM, Turtola H, Aalto-Setälä K, Top B, Frants RR, Kovanen PT, Syvänen
AC, Kontula K: The familial hypercholesterolemia (FH)-North Karelia muta-
tion of the low density lipoprotein receptor gene deletes seven nucleo-
tides of exon 6 and is a common cause of FH in Finland. J Clin Invest
1992, 90(1):219–228.
13. Amsellem S, Briffaut D, Carrié A, Rabès JP, Girardet JP, Fredenrich A, Moulin
P, Krempf M, Reznik Y, Vialettes B, de Gennes JL, Brukert E, Benlian P:
Intronic mutations outside of Alu-repeat-rich domains of the LDL recep-
tor gene are a cause of familial hypercholesterolemia. Hum Genet 2002,
111(6):501–510.
14. Laurie AD, Scott RS, George PM: Genetic screening of patients with
familial hypercholesterolaemia (FH): a New Zealand perspective.
Atheroscler Suppl 2004, 5(5):13–15.
15. Fouchier SW, Kastelein JJ, Defesche JC: Update of the molecular basis of
familial hypercholesterolemia in The Netherlands. Hum Mutat 2005,
26(6):550–556.
16. Sözen MM, Whittall R, Oner C, Tokatli A, Kalkanoğlu HS, Dursun A, Coşkun T,
Oner R, Humphries SE: The molecular basis of familial
hypercholesterolaemia in Turkish patients. Atherosclerosis 2005, 180(1):63–71.
17. Widhalm K, Dirisamer A, Lindemayr A, Kostner G: Diagnosis of families with
familial hypercholesterolaemia and/or Apo B-100 defect by means of
Komarova et al. BMC Medical Genetics 2013, 14:128 Page 5 of 5
http://www.biomedcentral.com/1471-2350/14/128DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis 2007,
30(2):239–247.
18. Pećin I, Whittall R, Futema M, Sertić J, Reiner Ž, Leigh SEA, Humphries SE:
Mutation detection in Croatian patients with familial hypercholesterolemia.
Ann Hum Genet 2013, 77(1):22–30.
19. Familial hypercholesterolemia due to defects in the gene encoding the
LDL receptor. In Mutations Occurring in Italy and their Analysis. iith edition.
Edited by Cantafora A, Prestinaci F, Blotta I.; 2006:90. Rapporti ISTISAN 06/23
[Article in Italian].
20. Gao F, Ihn HE, Medina MW, Krauss RM: A common polymorphism in the
LDL receptor gene has multiple effects on LDL receptor function.
Hum Mol Genet 2013 [Epub ahead of print].
21. Zakharova FM, Tatishcheva YA, Golubkov VI, Lipovetsky BM, Konstantinov
VO, Denisenko AD, Faergeman O, Vasilyev VB, Mandelshtam MY: Familial
hypercholesterolemia in St. Petersburg: diversity of mutations argues
against a strong founder effect. Russ J Genet 2007, 43(9):1046–1052
[Translated from Genetika 43: 1255–1262].
22. Zakharova FM, Golubkov VI, Mandelshtam MJ, Lipovetskii BM, Gaitskhoki VS:
Identification of novel missense mutation G571E, novel silent mutation
H229H, nonsense mutation C74X, and four single nucleotide
polymorphisms in the low-density lipoprotein receptor gene in patients
with familial hypercholesterolemia from St. Petersburg. Russ J Bioorg.
Chem 2001, 27((5):349–351 [Translated from Bioorganicheskaya Khimiya,
27(5):393–396].
23. Vieira JR, Whittall RA, Cooper JA, Miller GJ, Humphries SE: The A370T
variant (StuI polymorphism) in the LDL receptor gene is not associated
with plasma lipid levels or cardiovascular risk in UK men. Ann Hum Genet
2006, 70(Pt 6):697–704.
24. Warnich L, Kotze MJ, Langenhoven E, Retief AE: Detection of a frequent
polymorphism in exon 10 of the low-density lipoprotein receptor gene.
Hum Genet 1992, 89(3):362.
25. Tatishcheva YA, Mandelshtam MY, Golubkov VI, Lipovetsky BM, Gaitskhoki
VS: Four new mutations and two polymorphic variants of the low-
density lipoprotein receptor gene in familial hypercholesterolemia pa-
tients from St. Petersburg. Rus J Genet 2001, 37:1082–1086. Translated from
Genetika 37:1290–1295.
26. Giesel J, Weisshaar B, Oette K, Mechtel M, Doerfler W: Double Msp I RFLP in
the human LDL receptor gene. Nucl Acids Res 1987, 15:3943.
27. Mak YT, Pang CP, Tomlinson B, Zhang J, Chan YS, Mak TW, Masarei JR:
Mutations in the low-density lipoprotein receptor gene in Chinese famil-
ial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol 1998,
18(10):1600–1605.
doi:10.1186/1471-2350-14-128
Cite this article as: Komarova et al.: Familial hypercholesterolemia
mutations in Petrozavodsk: no similarity to St. Petersburg mutation
spectrum. BMC Medical Genetics 2013 14:128.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
